News

News Archive

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

Menarini Ricerche announces the completion of the dose escalation part of the First in Human, phase I/II DIAMOND trial (CLI24-001; NCT03008187) currently ongoing to evaluate SEL24/MEN1703
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

Menarini Group and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq:...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More